Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 5
2004 4
2005 2
2006 1
2007 4
2008 3
2009 1
2010 3
2011 1
2012 3
2013 2
2014 2
2016 3
2017 7
2018 10
2019 7
2020 12
2021 10
2022 7
2023 11
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Results by year

Filters applied: . Clear all
Page 1
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.
Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD; KEYNOTE-671 Investigators. Wakelee H, et al. N Engl J Med. 2023 Aug 10;389(6):491-503. doi: 10.1056/NEJMoa2302983. Epub 2023 Jun 3. N Engl J Med. 2023. PMID: 37272513 Free PMC article. Clinical Trial.
Immunotherapeutic Advances for NSCLC.
Massafra M, Passalacqua MI, Gebbia V, Macrì P, Lazzari C, Gregorc V, Buda C, Altavilla G, Santarpia M. Massafra M, et al. Among authors: gregorc v. Biologics. 2021 Oct 8;15:399-417. doi: 10.2147/BTT.S295406. eCollection 2021. Biologics. 2021. PMID: 34675481 Free PMC article. Review.
Mechanisms of resistance to osimertinib.
Lazzari C, Gregorc V, Karachaliou N, Rosell R, Santarpia M. Lazzari C, et al. Among authors: gregorc v. J Thorac Dis. 2020 May;12(5):2851-2858. doi: 10.21037/jtd.2019.08.30. J Thorac Dis. 2020. PMID: 32642198 Free PMC article. Review.
KRAS in NSCLC: State of the Art and Future Perspectives.
Cascetta P, Marinello A, Lazzari C, Gregorc V, Planchard D, Bianco R, Normanno N, Morabito A. Cascetta P, et al. Among authors: gregorc v. Cancers (Basel). 2022 Nov 4;14(21):5430. doi: 10.3390/cancers14215430. Cancers (Basel). 2022. PMID: 36358848 Free PMC article. Review.
Angiogenesis inhibition in lung cancer: emerging novel strategies.
Lazzari C, Bulotta A, Damiano G, Mirabile A, Viganó M, Veronesi G, Gregorc V. Lazzari C, et al. Among authors: gregorc v. Curr Opin Oncol. 2022 Jan 1;34(1):107-114. doi: 10.1097/CCO.0000000000000807. Curr Opin Oncol. 2022. PMID: 34812193 Review.
Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer.
Ciliberto G, Canfora M, Terrenato I, Agnoletto C, Agustoni F, Amoroso L, Baldassarre G, Curigliano G, Delmonte A, De Luca A, Fiorentino M, Gregorc V, Ibrahim T, Lazzari C, Mastronuzzi A, Pronzato P, Santoro A, Scambia G, Tommasi S, Vingiani A, Giacomini P, De Maria R. Ciliberto G, et al. Among authors: gregorc v. J Exp Clin Cancer Res. 2022 Oct 17;41(1):305. doi: 10.1186/s13046-022-02512-0. J Exp Clin Cancer Res. 2022. PMID: 36245005 Free PMC article.
Targeted Therapies in Early Stage NSCLC: Hype or Hope?
Friedlaender A, Addeo A, Russo A, Gregorc V, Cortinovis D, Rolfo CD. Friedlaender A, et al. Among authors: gregorc v. Int J Mol Sci. 2020 Aug 31;21(17):6329. doi: 10.3390/ijms21176329. Int J Mol Sci. 2020. PMID: 32878298 Free PMC article. Review.
Lung cancer screening: who pays? Who receives? The European perspectives.
Novellis P, Cominesi SR, Rossetti F, Mondoni M, Gregorc V, Veronesi G. Novellis P, et al. Among authors: gregorc v. Transl Lung Cancer Res. 2021 May;10(5):2395-2406. doi: 10.21037/tlcr-20-677. Transl Lung Cancer Res. 2021. PMID: 34164287 Free PMC article. Review.
94 results